Left Atrial Appendage Occlusion for Stroke Prevention in Atrial Fibrillation

Efficacy and Safety

• The American College of Cardiology recommends percutaneous LAA occlusion may be considered in patients with atrial fibrillation who have absolute contraindications for oral anticoagulation, but it remains a second-line option with limited evidence compared to oral anticoagulants 1, 2, 3
• LAA occlusion devices have been evaluated in randomized trials against warfarin, showing non-inferiority for the composite endpoint of stroke, systemic embolism, and cardiovascular death 4, 5
• The PROTECT-AF trial showed LAA closure was superior to warfarin for the primary efficacy endpoint of stroke, systemic embolism, and cardiovascular/unexplained death at a mean follow-up of 3.8 years 5, 6
• A patient-level meta-analysis of trials showed LAA closure was associated with comparable rates of the composite primary efficacy outcome but significantly lower hemorrhagic stroke and cardiovascular death 5, 6

Limitations and Concerns

• There are no randomized trials comparing LAA occlusion devices with newer direct oral anticoagulants (DOACs), which have better safety profiles than warfarin 1, 2, 5
• Serious periprocedural complications occur in approximately 6-7% of cases, including device embolization, major bleeding, and pericardial effusions requiring drainage 1, 2
• Thrombus formation on LAAO devices is not uncommon (up to 7.2% per year) and is associated with risk of ischemic stroke during follow-up 1, 2, 7

Patient Selection

• Current guidelines recommend LAA occlusion primarily for patients with high risk of stroke (CHA₂DS₂-VASc score ≥2 or 3) and absolute contraindications to long-term oral anticoagulation 1, 3, 4, 5

Specific Devices and Techniques

• The Lariat device uses an epicardial snare approach but has shown incomplete occlusion in approximately 20% of cases with inexperienced operators 1, 2
• Surgical LAA exclusion techniques show incomplete occlusion in up to 60% of cases and do not currently allow avoidance of oral anticoagulation in patients at risk of stroke 1, 2, 7
• The LAAOS III trial showed that surgical LAA occlusion during cardiac surgery reduced stroke risk when added to anticoagulation, but did not compare LAA occlusion alone versus anticoagulation 3

Current Guideline Recommendations

• The American College of Cardiology/American Heart Association/Heart Rhythm Society (2019) recommends percutaneous LAA occlusion may be considered in patients with AF at increased risk of stroke who have contraindications to long-term anticoagulation (Class IIb, Level of Evidence B-NR) 4
• The CHEST Guideline (2018) suggests LAA occlusion in patients with AF at high risk of ischemic stroke who have absolute contraindications for OAC (Weak recommendation, low quality evidence) 1, 2
• The European Society of Cardiology (2024) recommends percutaneous LAA occlusion may be considered in patients with AF and contraindications for long-term anticoagulant treatment (Class IIb) 3

Role of the Watchman Device in Managing Non-Valvular Atrial Fibrillation

Mechanism and Efficacy

• The left atrial appendage (LAA) is the source of approximately 90% of thrombi in patients with non-valvular atrial fibrillation, making it a logical target for stroke prevention strategies 8
• Two major randomized controlled trials, PROTECT AF and PREVAIL, have evaluated the Watchman device against warfarin, demonstrating its efficacy in preventing thromboembolism 9
• A meta-analysis of these trials showed that patients receiving the Watchman had significantly fewer hemorrhagic strokes than those on warfarin, though there was an initial increase in ischemic strokes in the device group 9
• When periprocedural events were excluded, the difference in ischemic stroke rates was not statistically significant 9

Patient Selection Criteria

• Primary candidates for the Watchman device are patients with non-valvular AF at high risk of stroke (CHA₂DS₂-VASc score ≥2 or ≥3) who have absolute contraindications to long-term oral anticoagulation, as recommended by the American College of Cardiology 9
• The FDA approval specifies that patients should be deemed suitable for short-term warfarin therapy during the periprocedural period 9
• Centers for Medicare & Medicaid Services (CMS) states the device is an option for patients suitable for short-term warfarin but deemed unable to take long-term oral anticoagulation 9

Procedural Considerations and Risks

• Serious periprocedural complications occur in approximately 6-7% of cases, including pericardial effusion requiring drainage 8
• A learning curve exists, with higher complication rates observed in the first few implantations at each center 8
• Post-implantation, dual antiplatelet therapy (DAPT) is typically required for at least 6 weeks, which may expose patients to increased bleeding risk 8
• Thrombus formation on the device is not uncommon (up to 7.2% per year) and is associated with risk of ischemic stroke during follow-up 8

Comparison with Oral Anticoagulants

• Oral anticoagulation remains the preferred first-line therapy for stroke prevention in most patients with AF and elevated stroke risk, according to the American College of Cardiology 9
• No randomized controlled trials have directly compared the Watchman device with direct oral anticoagulants (DOACs), which have better safety profiles than warfarin 8

Current Guideline Recommendations

• American College of Cardiology/American Heart Association/Heart Rhythm Society (2019): Percutaneous LAA occlusion may be considered in patients with AF at increased risk of stroke who have contraindications to long-term anticoagulation (Class IIb, Level of Evidence B-NR) 9, 10
• CHEST Guideline (2018): LAA occlusion is suggested in patients with AF at high risk of ischemic stroke who have absolute contraindications for oral anticoagulation (Weak recommendation, low quality evidence) 8

Antithrombotic Therapy for Patients with Watchman Devices

Standard Post-Implantation Antithrombotic Protocol

• The European Society of Cardiology recommends a three-phase approach for antithrombotic therapy following Watchman implantation, including Phase 1 (0-45 days) with warfarin and aspirin, Phase 2 (45 days to 6 months) with DAPT using aspirin and clopidogrel, and Phase 3 (>6 months) with aspirin monotherapy indefinitely 11

Clinical Implications and Monitoring

• The American Heart Association notes that the need for post-procedural antithrombotic therapy exposes patients to bleeding risks that may be equivalent to DOACs, creating a paradox for patients who received the device due to bleeding contraindications 11
• The European Society of Cardiology suggests that real-world practice differs significantly from trial protocols, with some centers using 3 months of DAPT alone or DOACs at full or reduced dose as alternatives to warfarin during the initial 45-day period 11

Alternative Regimens in Real-World Practice

• The American College of Cardiology recommends that patients with concurrent coronary artery disease requiring DAPT for stent thrombosis prevention should remain on DAPT beyond 6 months 12, 13, 14

Post‑WATCHMAN Antithrombotic Regimen in High‑Bleeding‑Risk Patients

Dual Antiplatelet Therapy at Discharge

• In patients with high bleeding risk who have undergone WATCHMAN implantation, discharge on dual antiplatelet therapy (aspirin 81–100 mg daily + clopidogrel 75 mg daily) is recommended. 15

Strategies to Reduce Major Bleeding During DAPT

• Co‑administration of a proton‑pump inhibitor (PPI) is advised to lower the incidence of gastrointestinal major bleeding while patients are on DAPT. 15
• Aspirin should be limited to a low dose (75–100 mg daily) rather than higher doses, to minimize bleeding risk without compromising antiplatelet efficacy. 15